Zhukovskaia E S, Gorbunova V A, Khvatova N V
Antibiotiki. 1976 Mar;21(3):273-7.
Systems of blood coagulation in patients treated with antibiotics of the anthracycline group were studied. Rubomycin was used in the treatment of patients with acute leukemia Adriamycin and carminomycin were used in the treatment of patients with solid tumors. The antibiotics affected the process of blood coagulation mainly through their cytostatic effect on thrombocytopoesis. Thrombocytopenia induced deficit of thrombocytal factors participating in the process of blood coagulation which resulted in hypocoagulation and hemorrhagic complications. The plasmic factors did not significantly change during the antibiotic therapy. A tendency to decrease in the levels of prothrombine, fibrinase and fibrinogen was noted which was possible due to an inhibitory effect of the antibiotics on the function of the reticuloendothelial tissue cells or indirectly to suppression of the tumor process. More pronounced changes in the system of blood coagulation of patients treated with rubomycin were probably associated with inferiority of the thrombocytal apparatus of the patients with acute leukemia treated with the antibiotic.
对接受蒽环类抗生素治疗的患者的血液凝固系统进行了研究。柔红霉素用于治疗急性白血病患者，阿霉素和卡米诺霉素用于治疗实体瘤患者。这些抗生素主要通过对血小板生成的细胞抑制作用来影响血液凝固过程。血小板减少症导致参与血液凝固过程的血小板因子缺乏，从而导致低凝状态和出血并发症。在抗生素治疗期间，血浆因子没有明显变化。观察到凝血酶原、纤维蛋白酶和纤维蛋白原水平有下降趋势，这可能是由于抗生素对网状内皮组织细胞功能的抑制作用，或间接由于肿瘤进程的抑制。接受柔红霉素治疗的患者的血液凝固系统中更明显的变化可能与用该抗生素治疗的急性白血病患者的血小板生成装置较差有关。
